Evolus, Inc. Common Stock (EOLS) Financials
EOLS Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 189.0 million | 209.7 million |
| 2023-09-30 | 168.0 million | 187.3 million |
| 2023-06-30 | 169.0 million | 175.9 million |
| 2023-03-31 | 160.2 million | 153.3 million |
EOLS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 452000 | 4.4 million |
| 2023-09-30 | -35.4 million | 4.6 million |
| 2023-06-30 | -13.5 million | 4.2 million |
| 2023-03-31 | -21.1 million | 3.3 million |
EOLS Net Income
No data available :(
EOLS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 62.8 million | - | 6.2 million |
| 2023-09-30 | 38.7 million | - | 6.3 million |
| 2023-06-30 | 41.7 million | - | 2.0 million |
| 2023-03-31 | 31.5 million | - | 2.3 million |
EOLS Shares Outstanding
EOLS Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 361000 | 2.4 million | 43.1 million | - |
| 2023-09-30 | 539000 | 1.6 million | 43.3 million | - |
| 2023-06-30 | 216000 | 1.2 million | 42.9 million | - |
| 2023-03-31 | 511000 | 1.4 million | 39.0 million | - |
EOLS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 61.0 million | 20.6 million |
| 2023-09-30 | 49.3 million | 15.4 million |
| 2023-06-30 | 49.3 million | 14.7 million |
| 2023-03-31 | 41.7 million | 12.1 million |
EOLS
Price: $13.21
52 week price:
Earnings Per Share: -1.08 USD
P/E Ratio: -12.23
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 16622
Market Capitalization: 815.5 million